Should You Buy Relmada Therapeutics Inc (RLMD) Stock Monday Morning?

Relmada Therapeutics Inc (RLMD) has gained Monday morning, with the stock climbing 3.00% in pre-market trading to 3.09. RLMD's short-term technical score of 3 indicates that the stock has traded less bullishly over the last month than 97% of stocks on the market. In the Biotechnology industry, which ranks 139 out of 146 industries, RLMD ranks higher than 8% of stocks. Relmada Therapeutics Inc has fallen 20.84% over the past month, closing at $3.78 on September 4. During this period of time, the stock fell as low as $2.79 and as high as $4.00. RLMD has an average analyst recommendation of Buy. The company has an average price target of $7.08.

RLMD has an Overall Score of 51. Find out what this means to you and get the rest of the rankings on RLMD!

See Full RLMD Report

Relmada Therapeutics Inc has a Long-Term Technical rank of 54. This means that trading over the last 200 trading days has placed the company in the upper half of stocks with 46% of the market scoring higher. In the Biotechnology industry which is number 136 by this metric, RLMD ranks better than 136% of stocks.

Important Dates for Investors in RLMD:

-Relmada Therapeutics Inc is set to release earnings on 2023-11-09. Over the last 12 months, the company has reported EPS of $-4.78. -We do not have a set dividend date for Relmada Therapeutics Inc at this time. Click Here To Get The Full Report on Relmada Therapeutics Inc (RLMD)